PALVELLA THERAPEUTICS, INC.
Palvella Therapeutics is a clinical-stage biopharmaceutical company developing therapies for serious, rare skin diseases and vascular malformations that have no FDA-approved treatments. Its QTORIN platform is designed to deliver drugs locally to deeper layers of the skin. The company’s lead candidate, QTORIN 3.9% rapamycin anhydrous gel, is in clinical development for microcystic lymphatic malformations and cutaneous venous malformations, and is also being developed for clinically significant angiokeratomas. QTORIN pitavastatin is a product candidate for disseminated superficial actinic porokeratosis, and Palvella has additional preclinical programs using the platform. Palvella develops product candidates and, if they receive regulatory approval, intends to commercialize them. It plans to build a focused U.S. specialty sales force and may use collaborators, distributors or other partners. The company is headquartered in Wayne, Pennsylvania.
Palvella Therapeutics will report Q3 earnings, with analysts expecting a loss of $1.80 per share, wider than the prior quarter. The FDA decision on its lead drug, QTORIN, is expected in 2027. All 16 analysts rate it a strong buy with a consensus price target of $228.40, implying 49% upside. The company has $250.6 million in cash, which it believes will last through the anticipated 2027 launch.
Palvella Therapeutics (PVLA) will release its Q3 2026 financial results on Nov. 5 before market open, followed by an investor conference call at 8:30 a.m. ET to discuss results and provide a corporate update. The webcast and replay will be available on the company's website.
Chardan Capital kept a Buy rating on Palvella Therapeutics with a $240 price target, suggesting 80.6% upside from the last close. The firm cites strong market potential in rare skin diseases and positive clinical development outlook, with FDA approval for QTORIN rapamycin expected in early 2027.
Over the past 7 days, AlphAI's AI scored 2 news stories mentioning PVLA (PALVELLA THERAPEUTICS, INC.). Coverage has been balanced: 0 bullish, 2 neutral, and 0 bearish.
Recent PVLA coverage spans financial news, earnings and regulation.
In the last 30 days, PVLA insiders filed 20 SEC Form 4 transactions — no purchases and 20 sales ($4.1M). The most active reporter was JENKINS GEORGE M with 17 filings. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
Earnings and forward-looking FDA and commercialization readiness signals are likely to drive near-term repricing versus the current high valuation.
The earnings announcement date may trigger pre‑market positioning and heightened volatility around the release.
Chardan Capital kept a Buy rating on Palvella Therapeutics with a $240 price target, suggesting 80.6% upside from the last close. The firm cites strong market potential in rare skin diseases and positive clinical development outlook, with FDA approval for QTORIN rapamycin expected in early 2027.
Priority Review acceptance increases probability of earlier FDA action and keeps the Phase 3 SELVA efficacy narrative in focus for PVLA’s microcystic lymphatic malformations program.
Positive regulatory milestone likely to lift the stock as investors price in potential approval.
AlphAI scores every news story that mentions PVLA with an AI model for sentiment and relevance, and aggregates insider trades from PALVELLA THERAPEUTICS, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Palvella Therapeutics will report Q3 earnings, with analysts expecting a loss of $1.80 per share, wider than the prior quarter. The FDA decision on its lead drug, QTORIN, is expected in 2027. All 16 analysts rate it a strong buy with a consensus price target of $228.40, implying 49% upside. The company has $250.6 million in cash, which it believes will last through the anticipated 2027 launch.
6 min readPalvella Therapeutics (PVLA) will release its Q3 2026 financial results on Nov. 5 before market open, followed by an investor conference call at 8:30 a.m. ET to discuss results and provide a corporate update. The webcast and replay will be available on the company's website.
1 min readChardan Capital kept a Buy rating on Palvella Therapeutics with a $240 price target, suggesting 80.6% upside from the last close. The firm cites strong market potential in rare skin diseases and positive clinical development outlook, with FDA approval for QTORIN rapamycin expected in early 2027.
1 min readPalvella Therapeutics (PVLA) received FDA acceptance and Priority Review for its QTORIN rapamycin NDA, targeting a February 28, 2027 decision. The NDA seeks approval to treat microcystic lymphatic malformations, a condition with no current FDA-approved therapies. Phase 3 SELVA results showed statistical significance across all efficacy endpoints. Palvella plans a potential U.S. launch in early 2027 if approved.
1 min readPALVELLA THERAPEUTICS, INC. (PVLA) filed an SEC Form 8-K — Other Events. Palvella Announces FDA Acceptance and Priority Review of QTORIN™ Rapamycin NDA; February 28, 2027 PDUFA Target Action Date Set QTORIN™ rapamycin could become the first FDA-approved therapy for microcystic lymphatic malformations, a serious, lifelong rare disease affecting an esti
2 min readPalvella Therapeutics (PVLA) is preparing to launch QTORIN rapamycin for Microlymphatic Malformation (MLM), a rare genetic disease, with an estimated 30,000 patients in the U.S. The company expects to price the treatment at $100,000 to $200,000 per patient annually and sees a potential $1 billion peak sales opportunity. Palvella is also developing QTORIN rapamycin for cutaneous venous malformations (CVM) and plans to disclose two additional disease programs by year-end.
3 min readGoin Kathleen (Chief Operating Officer) sold 4,313 shares of PALVELLA THERAPEUTICS, INC. (PVLA) at an average of $124.58 ($123.62–$126.19, $0.54M total) across 3 trades on 2026-10-21 under a Rule 10b5-1 trading plan.
1 min readPalvella Therapeutics (PVLA) presented its rare-disease strategy at Chardan's conference, targeting a commercial launch in 2025. The company raised $230M in 2024, filed an NDA for QTORIN rapamycin, and expects an FDA decision by late October. Palvella is expanding its pipeline to six indications by year-end, with a focus on skin and vascular anomaly diseases. Management anticipates peak sales of $1B-$3B for its lead programs.
3 min readH.C. Wainwright reiterated a Buy rating and $246 price target for Palvella Therapeutics (PVLA) after positive pediatric data from dermatology conferences. The stock trades at $122.96, with a Strong Buy consensus and targets ranging from $205 to $267. Palvella presented data from Phase 3 SELVA and Phase 2 TOIVA trials, showing strong responses in young patients. The company reported a Q2 loss of $1.52 per share, wider than expected, but has $251 million in cash.
2 min readRaymond James reiterated a Strong Buy rating and $226.00 price target for Palvella Therapeutics (NASDAQ:PVLA) after its presentation at a dermatology conference. The data showed positive results for QTORIN rapamycin in pediatric patients, supporting a broad potential label. Despite an 8.2% weekly decline, the stock is up 74% over the past year. Palvella reported a wider-than-expected Q2 loss but has $251 million in cash for development.
2 min read
